Sidney Broder, MD
Neuromusculoskeletal Medicine & OMM · Grand Blanc, MINPI 1851465025
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,210 of the $1,702 with a category attached, or 71.1%. 20 manufacturers reported payments, led by Biogen at 40.4% of the total. 2025 is the largest year on record at $860, 2.2 times the $383 reported in 2019. Among neuromusculoskeletal medicine & omm clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$687
- AbbVie$439
- Aucta Pharmaceuticals, Inc.$118
- Novartis$86
- Eisai Inc.$53
- Teva Pharmaceuticals USA, Inc.$40
- plus $278 from 14 others
What the payments were for
- Consulting fees$45026%
- Food & beverage$1,21071%
- Education$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 28 | $687 |
| AbbVie | 46 | $439 |
| Aucta Pharmaceuticals, Inc. | 6 | $118 |
| Novartis | 5 | $86 |
| Eisai Inc. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $33 |
| Cycle Pharmaceuticals Inc | 2 | $29 |
| Livanova USA, Inc. | 1 | $27 |
| Tanabe Pharma America, Inc. | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| EMD Serono, Inc. | 1 | $22 |
| UCB, Inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$450
How this compares
$1,702 in reported general payments places this provider in the 95th percentile of 41 neuromusculoskeletal medicine & omm providers in Michigan.
See all neuromusculoskeletal medicine & omm providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 24 | $194,398 |
| Teriflunomide | 31 | $118,977 |
| Kesimpta PenOfatumumab | 12 | $103,146 |
| CopaxoneGlatiramer Acetate | 13 | $71,217 |
| FingolimodFingolimod Hcl | 25 | $53,388 |
| GlatopaGlatiramer Acetate | 12 | $33,973 |
| Glatiramer Acetate | 23 | $31,931 |
| Nurtec OdtRimegepant Sulfate | 25 | $30,993 |
| Dimethyl Fumarate | 28 | $27,496 |
| QuliptaAtogepant | 19 | $21,191 |
| UbrelvyUbrogepant | 17 | $18,843 |
| BriviactBrivaracetam | 12 | $17,427 |
| Lacosamide | 88 | $11,888 |
| Emgality PenGalcanezumab-Gnlm | 14 | $9,481 |
| ValtocoDiazepam | 13 | $8,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $687 | $194,39824 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $40 | $71,21713 claims |
| AbbVieQulipta, Ubrelvy | $439 | $40,03436 claims |
| UCB, Inc.Briviact | $16 | $17,42712 claims |
| Neurelis, Inc.Valtoco | $14 | $8,52213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 neuromusculoskeletal medicine & omm providers in Michigan.
Other neuromusculoskeletal medicine & omm in Grand Blanc
- Max FeinsteinBloomfield Hills$8K
- Mark BradenGrand Rapids$8K
- Reddog SinaEast Lansing$1K
- Mark BeardNovi$533
- David NebbelingLansing$479
- David HicklingClinton Twp$477
- Zachary WilsonEast Lansing$448
- Benjamin VisgerMuskegon$444
- Amy DeanMuskegon$340
- Justin RuttEast Lansing$308
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.